This survey study examines how transgender and gender nonconforming individuals have experienced oral healthcare, how accessible such care is to them, and how they feel about receiving it. Read More

18 or greater years of age
self-identify as transgender or gender nonconforming

This is a study to evaluate the efficacy of Chemo Mouthpiece® in minimizing patient-reported symptoms associated with oral mucositis in cancer patients receiving chemotherapy. The Chemo Mouthpiece(R) is a novel device to make it easier to deliver cryotherapy (ice chips). Read More

Aged 18-80 years
Planned to receive at least 2 cycles of infused stomatotoxic chemotherapy regimens
Be willing and able to complete all study-related activities

Study will assess adult participants for gum disease and bacteria in the mouth. The dental exams are the same exams that normally take place in dentist’s office. Saliva and plaque will be collected from participants. Visits will be every 2 weeks or every month. Study lasts 10-12 months. Read More

At least 25 years old
At least sixteen (16) teeth
To be determined at Screening Visit: Presence of at least 4 sites (anterior or posterior) with probing pocket depths (PD) > 5 mm and < 6 mm and concomitant clinical attachment loss.
To be determined by testing subgingival plaque after the Screening Visit: Have detectable Pg in subgingival plaque as assessed by PCR (we will take sampl...

Participants will be asked questions about a new cognitive processing test (how fast they can think). This study involves a single visit which takes about 20-minutes at the Conventus Medical Center in Buffalo. 50 multiple sclerosis patients and 50 healthy people will be enrolled. Read More

Physician established diagnosis of multiple sclerosis
18 years of age or older
Able to read and speak English
Not pregnant

Study to evaluate reducing worry, anxiety, and stress in underserved communities highly impacted by the COVID-19 pandemic. Mindfulness Based Stress Reduction programs (meditation, breathing and movement) will be delivered via video / teleconference or a smart phone APP. The study lasts approximately 21 weeks. Read More

Inclusion:
(1) age 18 years and older
(2) a baseline score ≥26 (clinically significant worry) on the Penn State Worry Questionnaire-Abbreviated
(3) fluency in English
(4) reside in one of the underserved, census-identified primarily African American communities in Buffalo, NY
Exclusion:
(5) severe depression
(6) active suicidal intent
(7) DSM-V diagno...

This study enrolls men with prostate cancer. The purpose of this study is to compare using radium-223 and docetaxel chemotherapy treatment vs. using docetaxel alone in men with Metastatic Castration-Resistant Prostate Cancer (mCRPC). Radium223 has been FDA approved to treat men with prostate cancer that has spread to the bone, but it has not been approved for men with cancer that has spread to soft tissue or in combination with the chemotherapy drug docetaxel. Read More

Adults ages 18+.
Males with progressive Metastatic Prostate Cancer.
Have 2+ bone lesions.

This study enrolls adults diagnosed with head and neck cancer who have plans to complete chemoradiotherapy. The purpose of this study is to learn the best timing for feeding tube placement and speech therapy to create the best quality of life for patients. Read More

Adults ages 18+.
Patients with Head and Neck Cancer being treated at ECMC and Cancer Care WNY.
Patients planning to receive concurrent chemo-radiation therapy.

This study enrolls adults who have had a brain hemorrhage within the last 7 days. The purpose of the study is to learn whether it is better to keep taking or stop taking the medication statin after having a brain bleed. Read More

Adults ages 50+.
Have had bleeding in the brain (brain hemorrhage) within the last 7 days.
Were taking a statin drug.
People who may be eligible for this study will be contacted by study staff directly. Eligible participants will be inpatients of Buffalo General/Gates Vascular Institute.

This study enrolls people who have been diagnosed with Tricuspid Regurgitation (TR). The purpose of this study is to look at the safety and effectiveness of this new investigational device compared to the standard medical treatment. Read More

Adults ages 18+
Diagnosed with Tricuspid Regurgitation/Insufficiency

This is a 26-week open-label study to evaluate the safety and effectiveness of the study drug in the treatment of pediatric participants with schizophrenia or bipolar I disorder. Read More

Males and females ages 13 to 18 with schizophrenia or 10 to 18 years of age with bipolar I disorder may be eligible for the study.